Experience with the systemic treatment of severe forms of psoriasis

Biomedical Papers

Volumn 156, Issue 1, 2012, Pages 29-40

  Tichy, Martin ^a   Zapletalova, Jana ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Adalimumab; Biological therapy; Conventional therapy; Etanercept; Infliximab; Psoriasis; Systemic therapy; Ustekinumab

Indexed keywords

ADALIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; USTEKINUMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PSORIASIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859447730     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.007     Document Type: Article

References (34)

1. Tichý M, Ditrichová D. Biologicals in the treatment of severe forms of psoriasis. Dermatol praxi 2007;1:19-21.
2. Tichý M, Ditrichová D. Biological treatment in dermatology. Klin Farmakol Farm 2008;22(2):68-71.
3. Bachmann F, Nast A, Sterry W, Philipp S. Safety and efficacy of the tumor necrosis factor antagonists. Semin Cutan Med Surg 2010;29(1):35-47. Review.
4. Kurzeja M, Rudnicka L, Olszewska M. New interleukin - 23 pathway inhibitors in dermatology: ustekinumab, briakinumab and secukinumab. Am J Clin Dermatol 2011;12(2):113-25.
5. van de Kerkhof PCM, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba Z, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J. One weekly administration of etanercept 50mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177-85.
6. Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011;12(5):321-37.
7. Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss - of - response and anti - infliximab antibody induction. Br J Dermatol (Epub ahead of print).
8. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B. Long-term safety experience of ustekinumab in patients with moderate - to - severe psoriasis (Part I of II): Results from analyse of general safety from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2011 (Epud ahead of print).
9. Benáková N, Štork J. Treatment of Psoriasis with Biologicals. Consensual Guidelines of The Czech Dermatovenereological Society of the CMA JEP 2006. Čes Slov Derm 2006;81(4):S1-11.
10. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJG, Chandler DA, Finlay AY, Griffiths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists ́ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161(5):987-1019.
11. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret R, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SR, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, Van de Kerkhof P, Rzany B. European S3- Guidelines on systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(suppl. 2):1-70.
12. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J, Canadian Psoriasis Guidelines Committee. Canadian giudelines for the management of plaque psoriasis: overview. J Cutan Med Surg 2011;15(4):192-200.
13. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich K, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303(1):1-10.
14. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65(1):137-74. Review.
15. Ettler K. Indexy v klinickém hodnocení psoriázy a atopického ekzému. Čes-slov Derm 1995;70(1):45-7.
16. Benáková N, Ettler K, Štork J, Vašků V. Psoriáza nejen pro praxi, Praha: Triton; 2007,164 s.
17. Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatol Treat 2007;18:223-42.
18. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
19. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006;20:52-5.
20. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concept of pathogenesis. Ann Rheum Dis 2005;64:30-6.
21. Vašků V. Comorbidities in psoriasis - a new perspective of an old disease. Dermatol praxi 2009;3(2):63-6.
22. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158:549-57.
23. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161-8.
24. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35.
25. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007;157:1275-7.
26. Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an openlabel, multicenter, phase III study. Int J Dermatol 2007;46:637-48.
27. Smith KC. Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett 2000;6:1-2;5.
28. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006;33:1442-6.
29. Giannetti A. Commentary on the European S3- Guidelines on the systemic treatment of Psoriasis. J Eur Acad Dermatol Venereol 2010;24:p.368.
30. Tichý M, Ditrichová D. Commentary to the Guidelines of The European Dermatology Forum on the Systemic Treatment of Psoriasis Vulgaris. Čes-slov Derm 2010;85(4):215-8.
31. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84.
32. Smith CH, Barker JNWN. Psoriasis and its management. BMJ 2006;333:380-4.
33. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998;139:88-95.
34. Murray HE, Anhalt AW, Lessard R, Schacter RK, Ross BJ, Stewart WD, Geiger JM. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dematol 1991;24:598-602.